or Try an Advanced Search...

    Technical Analysis for RPHM - Reneo Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 1.61 0.47% 0.01
    RPHM closed down 1.23 percent on Wednesday, May 15, 2024, on 1.47 times normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RPHM trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.47%
    Calm After Storm Range Contraction 0.47%
    Inside Day Range Contraction 0.47%
    Gapped Down Weakness 0.47%
    Volume Surge Other -0.77%
    Wide Range Bar Range Expansion -0.77%
    Lower Bollinger Band Walk Weakness -0.77%
    Gapped Down Weakness -0.77%
    Lower Bollinger Band Touch Weakness -0.77%
    Fell Below 20 DMA Bearish 1.10%
    Older End-of-Day Signals for RPHM ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 2 hours ago
    Down 1% about 2 hours ago
    Up 1% about 2 hours ago
    Possible Inside Day about 22 hours ago
    Up 1% about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    RPHM Chart by TradingView
    Basic chart:

    Profile

    Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors

    Is RPHM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise
    May 13 Reneo Pharmaceuticals gains on deal to merge with OnKure
    May 13 Reneo Pharmaceuticals and OnKure Announce Proposed Merger
    May 7 Reneo Pharmaceuticals GAAP EPS of -$0.25
    May 7 Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
    Mar 28 Reneo Pharmaceuticals GAAP EPS of -$2.52
    Mar 28 Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
    Mar 25 Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
    Dec 27 Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Dec 21 These Stocks under $10 Are Poised To Explode
    See more RPHM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.45
    52 Week Low 0.9801
    Average Volume 289,834
    200-Day Moving Average 4.20
    50-Day Moving Average 1.69
    20-Day Moving Average 1.71
    10-Day Moving Average 1.73
    Average True Range 0.10
    RSI (14) 40.12
    ADX 31.23
    +DI 17.12
    -DI 31.96
    Chandelier Exit (Long, 3 ATRs) 1.63
    Chandelier Exit (Short, 3 ATRs) 1.71
    Upper Bollinger Bands 1.85
    Lower Bollinger Band 1.57
    Percent B (%b) 0.11
    BandWidth 16.43
    MACD Line 0.00
    MACD Signal Line 0.01
    MACD Histogram -0.0143
    Fundamentals Value
    Market Cap 53.3 Million
    Num Shares 33.3 Million
    EPS -2.36
    Price-to-Earnings (P/E) Ratio -0.68
    Price-to-Sales 0.00
    Price-to-Book 0.48
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.72
    Resistance 3 (R3) 1.72 1.69 1.70
    Resistance 2 (R2) 1.69 1.66 1.69 1.69
    Resistance 1 (R1) 1.64 1.64 1.67 1.64 1.69
    Pivot Point 1.61 1.61 1.62 1.61 1.61
    Support 1 (S1) 1.56 1.58 1.59 1.56 1.51
    Support 2 (S2) 1.53 1.56 1.53 1.51
    Support 3 (S3) 1.48 1.53 1.50
    Support 4 (S4) 1.48